Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen Licenses RNA Technology to Focus Diagnostics

NEW YORK (GenomeWeb News) – Quest Diagnostics subsidiary Focus Diagnostics has licensed non-exclusive, worldwide rights to Asuragen’s Armored RNA technology for use in molecular diagnostic products, the firms said today.
 
The Armored RNA technology was jointly developed by Austin, Texas-based Asuragen and reference lab Cenetron Diagnostics for the packaging of RNA or DNA in bacteriophage coat proteins for protection and stabilization. According to the firms, the technology armors the RNA standard against the hazards of nucleases in patient samples.
 
Asuragen will develop and supply reagents for Focus in its QSR-compliant manufacturing facility. Other terms of the agreement were not disclosed.
 
Asuragen is a spin off of RNAi technologies firm Ambion, which was acquired by Applied Biosystems at the end of 2005 for around $273 million.
 

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.